Disclosed herein are materials and methods for the treatment of stress-related disorders and cancer.

The present disclosure provides a GLP1 analogue and GLP1/GIP receptor co-agonist analogues, a fusion protein comprising the GLP1 analogue or the GLP1/GIP receptor co-agonist analogue, and methods of use thereof. In various embodiments of the invention, the fusion protein comprises the GLP1 analogue or the GLP1/GIP receptor co-agonist analogue fused to a protecting antibody or further fused to a stabilizing domain. In some embodiments, the fusion proteins are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

Provided for herein are anti-GIP antibodies, or antigen-binding fragments thereof. Conjugates of the anti-GIP antibodies, or antigen-binding fragments thereof, to biologically active peptides are also provided. Pharmaceutical compositions of the, anti-GIP antibodies, or antigen-binding fragments thereof, biologically active peptides, combinations thereof, or conjugates thereof are also provided. Methods of using the embodiments and compositions provided for herein are also provided.